Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "antisense oligonucleotides" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-11 z 11
    Tytuł:
    Multidrug resistance-associated protein - reduction of expression in human leukaemia cells by antisense phosphorothioate olignucleotides.
    Autorzy:
    Niewiarowski, Wojciech
    Gendaszewska, Edyta
    Rębowski, Grzegorz
    Wójcik, Marzena
    >Mikołajczyk, Barbara
    Soszyński, Mirosław
    Bartosz, Grzegorz
    Powiązania:
    https://bibliotekanauki.pl/articles/1044273.pdf
    Data publikacji:
    2000
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    antisense oligonucleotides
    MRP
    multidrug resistance
    Opis:
    Multidrug resistance-associated protein (MRP1) causes cellular drug resistance in several cancer cell lines. In this paper we show that antisense oligonucleotides decrease MRP1 expression in human leukaemia cells. We investigated biological activity of a series of 12 linear phosphorothioate oligonucleotides, complementary to several regions of MRP1 mRNA. The oligonucleotides were administered to leukaemia HL60/ADR cells overexpressing MRP1 protein. Then, the level of MRP1 mRNA was determined by means of semiquantitative RT-PCR and the protein level by reaction with specific monoclonal antibodies. Some of the investigated antisense oligonucleotides decrease the expression level of the MRP1 protein by 46% and its mRNA level by 76%.
    Źródło:
    Acta Biochimica Polonica; 2000, 47, 4; 1183-1188
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    RNA modulation, repair and remodeling by splice switching oligonucleotides.
    Autorzy:
    Kole, Ryszard
    Williams, Tiffany
    Cohen, Lisa
    Powiązania:
    https://bibliotekanauki.pl/articles/1043268.pdf
    Data publikacji:
    2004
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    RNA splicing; antisense oligonucleotides; genetic disease
    Opis:
    Targeting splicing by antisense oligonucleotides allows RNA modifications that are not possible with RNA interference or other antisense techniques that destine the RNA for destruction. By changing the ratio of naturally occurring splice variants the expression of mRNA is modulated. By preventing the use of an aberrant splice site created by a mutation and enforcing re-selection of correct splice sites the RNA is repaired. Antisense induced skipping of the exon that carries a nonsense mutation remodels the mRNA and restores the reading frame of the defective protein. All of the above approaches have clinical applications. Modulation of splice variants is particularly important since close to 60% of all genes code for alternatively spliced pre-mRNA.
    Źródło:
    Acta Biochimica Polonica; 2004, 51, 2; 373-378
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Civilization diseases – therapeutic application of antisense strategy
    Autorzy:
    Bąkowska-Żywicka, Kamila
    Tyczewska, Agata
    Twardowski, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/703440.pdf
    Data publikacji:
    2008
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    civilization diseases
    antisense oligonucleotides
    novel therapies
    Opis:
    Modulation and regulation of biosynthesis process by means of antisense oligonucleotides lay the foundation for new therapeutic strategies, among others against cancer, viral or angiogenesis diseases. The aim of this account is the presentation of molecular basis of antisense strategy and mechanism of action of antisense oligonucleotides. Furthermore we present the state of art in clinical studies of application of antisense oligonucleotides in some of civilization diseases.
    Źródło:
    Nauka; 2008, 1
    1231-8515
    Pojawia się w:
    Nauka
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Tissue distribution of a menthyl-conjugated oligodeoxyribonucleotide antisense to PAI-1 mRNA
    Autorzy:
    Szemraj, Janusz
    Al-Nedawi, Khalid
    Chabielska, Ewa
    Buczko, Wlodzimierz
    Pawlowska, Zofia
    Powiązania:
    https://bibliotekanauki.pl/articles/1041329.pdf
    Data publikacji:
    2005
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    PAI-1
    antisense oligonucleotides
    tissue distribution
    Opis:
    The inhibitory effect of numerous analogues of PO-16, an hexadecadeoxyribonucleotide antisense to sequences -22 to -17 of PAI-1 mRNA coding for a fragment of the signal peptide, on the expression of PAI-1 in endothelial cells, and physiological consequences of the subsequently reduced PAI-1 activity tested in vitro and in vivo, were described in our previous studies. Of particular interest was PO-16 5'-O-conjugated with menthyl phosphorothioate (MPO-16R). In this work, tissue localisation of MPO-16R labelled with [35S] phosphorothioate at the 3'-end, was determined. [35S]MPO-16R and control [35S]MPO-16R-SENSE oligonucleotides were administered intravenously into 22 rats and organ distribution of the labelled bioconjugates was assessed after 24 and 48 h. For this purpose, tissue sections were subjected to autoradiography, and quantitated by liquid scintillation after solubilisation. Overall clearance of radioactivity was already seen after 24 h, with the radioactivity recovered mainly in the kidney and liver. A smaller fraction of radioactivity was also retained in the spleen and heart. The kidney concentration of the labelled probe was higher than that of liver by 50%. The distribution of PAI-1 mRNA in untreated rat kidney, liver, spleen and heart established by two independent techniques: Ribonuclease Protection Assay and Real-Time PCR, shows the same pattern as that observed for [35S]MPO-16R antisense.
    Źródło:
    Acta Biochimica Polonica; 2005, 52, 4; 849-855
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    A breakthrough in the efficiency of contact DNA insecticides: rapid high mortality rates in the sap-sucking insects Dynaspidiotus britannicus Comstock and Unaspis euonymi Newstead
    Autorzy:
    Gal`chinsky, N.
    Useinov, R.
    Yatskova, E.
    Laikova, K.
    Novikov, I.
    Gorlov, M.
    Trikoz, N.
    Sharmagiy, A.
    Plugatar, Y.
    Oberemok, V.
    Powiązania:
    https://bibliotekanauki.pl/articles/2082776.pdf
    Data publikacji:
    2020
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    antisense oligonucleotides
    DNA insecticides
    insect pest control
    sap-sucking
    insects
    28S ribosomal RNA
    Opis:
    In this short communication describing experiments carried out on the larvae of two insects, Unaspis euonymi Comstock (feeding on Euonymus japonicus Thunb.) and Dynaspidiotus britannicus Newstead (feeding on Laurus nobilis L.), we evaluate for the first time the efficiency of using DNA insecticides in the control of sap-sucking insects, including armored scale insects. Over a period of 10 days, high insect mortality was detected in both U. euonymi and D. britannicus, accompanied by a significant decrease in the concentration of target RNAs. At the same time, no visible changes were observed when the leaves of the host plants were subjected to treatment with DNA insecticides for one month. The results show the high efficiency of DNA insecticides used against hemipteran insect pests. It is noteworthy that the high efficiency of DNA insecticides and their low cost in comparison with RNA preparations provides a safe and extremely promising potential vehicle for the control of sap-sucking insects.
    Źródło:
    Journal of Plant Protection Research; 2020, 60, 2; 220-223
    1427-4345
    Pojawia się w:
    Journal of Plant Protection Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Insecticidal activity of three 10–12 nucleotides long antisense sequences from 5.8S ribosomal RNA gene of gypsy moth Lymantria dispar L. against its larvae
    Autorzy:
    Oberemok, V.V.
    Laikova, K.V.
    Useinov, R.Z.
    Gal`chinsky, N.V.
    Novikov, I.A.
    Yurchenko, K.A.
    Volkov, M.E.
    Gorlov, M.V.
    Brailko, V.A.
    Plugatar
    Powiązania:
    https://bibliotekanauki.pl/articles/2084849.pdf
    Data publikacji:
    2019
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    antisense oligonucleotides
    DNA insecticides
    gypsy moth
    insect pest control
    Lymantria dispar
    5.8S ribosomal RNA
    Opis:
    5.8S ribosomal RNA plays an important role in protein synthesis and eukaryotic ribosome translocation. Contact DNA insecticides based on antisense fragments of 5.8S ribosomal RNA gene of gypsy moth Lymantria dispar L. showed prospective insecticidal activity on its larvae. The most pronounced insecticidal effect was found for antisense fragments 10 and 11 nucleotides long (oligoRIBO-10 and oligoRIBO-11), whereas 12 nucleotides long fragment (oligoRIBO-12) caused the lowest level of insect mortality. This data corresponds to results obtained earlier using rabbit reticulocyte and wheat germ extracts, where maximum inhibition of protein synthesis was observed when a relevant oligomer 10-11 nucleotides long was used, whilst longer chain lengths resulted in reduced inhibition. Using oligoRIBO-11 fragment we have shown penetration of antisense oligonucleotides to insect cells through insects’ exoskeletons. MALDI technique registered the penetration of the oligoRIBO-11 fragment into insect cells after 30 min and a significant response of insect cells to the applied oligonucleotide after 60 min, which indicates not only that the oligonucleotide enters the insect cells, but also the synthesis of new substances in response to the applied DNA fragment. Contact DNA insecticides developed from the L. dispar 5.8S ribosomal RNA gene provide a novel biotechnology for plant protection using unmodified antisense oligonucleotides.
    Źródło:
    Journal of Plant Protection Research; 2019, 59, 4; 561-564
    1427-4345
    Pojawia się w:
    Journal of Plant Protection Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Proces składania RNA jako cel oddziaływania terapeutycznego
    Therapeutic targeting of alternative splicing
    Autorzy:
    Paluszczak, Jarosław
    Powiązania:
    https://bibliotekanauki.pl/articles/762699.pdf
    Data publikacji:
    2019-12-29
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    alternatywne składanie RNA
    antysensowne oligonukleotydy
    nusinersen
    eteplirsen
    modulatory składania RNA
    alternative splicing
    antisense oligonucleotides
    RNA splicing modulators
    Opis:
    Gene transcription leads to the generation of pre-mRNA molecules which contain both coding sequences (exons) and intervening non-coding sequences (introns). The primary transcript needs further processing which involves the excision of introns and ligation of exons. This process is called RNA splicing. Nearly all primary transcripts undergo alternative forms of splicing, which may lead to exon skipping or intron inclusion in the final mRNA. Thus, the translation of alternatively spliced RNA molecules results in the formation of slightly different proteins, which may, in some cases, exert antagonistic activity. Splicing is a multistage process which is conducted by a complex machinery comprising small nuclear RNA molecules and many proteins called splicing factors. The process undergoes precise regulation by means of cis acting internal RNA sequences and trans acting protein factors which may either enhance or silence the splicing of an exon. Many diseases are associated with aberrations of alternative splicing and its modulation may be used therapeutically, e.g. for the treatment of spinal muscular atrophy (SMA) or Duchenne muscular dystrophy (DMD). This article presents current knowledge of the ways of pharmacological modulation of alternative splicing. The focus is on the use of those therapeutics which have been already approved for clinical application or have entered clinical trials. The chemistry and mechanism of action of specific splice switching oligonucleotides is presented. Nusinersen promotes exon inclusion during splicing of SMN2 and is used for SMA treatment. On the other hand, eteplirsen is an oligonucleotide promoting exon skipping during splicing of mutated DMD and has been conditionally approved for DMD treatment. Moreover, small molecule modulators of alternative splicing (e.g. branaplam) are also described. The dynamic developments in this field should result in the approval of new drugs acting by the modulation of alternative splicing in the nearest future.
    Powstająca w wyniku transkrypcji genu cząsteczka pre-mRNA zawiera odcinki kodujące (eksony) poprzedzielane odcinkami niekodującymi (intronami). Pierwotny transkrypt wymaga obróbki, która polega między innymi na wycinaniu intronów i łączeniu eksonów. Proces ten nazywany jest składaniem RNA. W przypadku niemal wszystkich transkryptów, składanie pre-mRNA przebiega w komórkach alternatywnymi drogami, na przykład prowadząc do wykluczenia jednego z eksonów z ostatecznego transkryptu, lub włączenia jednego z intronów. Proces składania RNA przeprowadzany jest przez skomplikowaną maszynerię złożoną z małych cząsteczek RNA i białek, i podlega precyzyjnej regulacji. Wiele chorób związanych jest z nieprawidłowościami alternatywnego składania RNA, a modulacja tego procesu może być wykorzystana terapeutycznie, między innymi w leczeniu rdzeniowego zaniku mięśni (SMA, ang. spinal muscular atrophy) czy dystrofii mięśniowej Duchenne’a (DMD). Celem artykułu jest przedstawienie wiedzy na temat farmakologicznych możliwości wpływania na proces składania RNA. Nacisk położono na scharakteryzowanie tych terapeutyków, które zostały już zarejestrowane do użytku klinicznego, lub które są w trakcie zaawansowanych badań klinicznych. Zaprezentowano budowę chemiczną i mechanizm działania oligonukleotydowych przełączników składania RNA. Nusinersen stymuluje włączanie eksonu 7 w trakcie składania SMN2 i jest wykorzystywany w leczeniu SMA. Eteplirsen, który stymuluje pomijanie eksonu 51 w trakcie składania zmutowanych wariantów DMD, został warunkowo dopuszczony do leczenia DMD w USA. Opisano także drobnocząsteczkowe modulatory alternatywnego składnia RNA, np. branaplam. Dynamiczny rozwój tego obszaru badań stwarza szansę na wprowadzone w najbliższej przyszłości do lecznictwa kolejnych leków, których mechanizm działania oparty będzie na modulacji alternatywnego składania RNA.
    Źródło:
    Farmacja Polska; 2019, 75, 11; 605-616
    0014-8261
    2544-8552
    Pojawia się w:
    Farmacja Polska
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Synteza modyfikowanych oligonukleotydów zawierających stereozdefiniowane internukleotydowe wiązania tiofosforanowe
    Synthesis of modified oligonucleotides containing stereodefined internucleotide phosphorothioate bonds
    Autorzy:
    Radzikowska, E.
    Kaczmarek, R.
    Baraniak, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/172219.pdf
    Data publikacji:
    2015
    Wydawca:
    Polskie Towarzystwo Chemiczne
    Tematy:
    oligonukleozydotiofosforany
    oligonukleotydy antysensowe
    synteza modyfikowanych oligonukleotydów
    synteza stereospecyficzna
    oligo(deoxy)ribonucleoside phosphorothioates
    antisense oligonucleotides
    synthesis of modified oligonucleotide
    stereospecific synthesis
    Opis:
    Synthetic oligonucleotides constitute an important class of compounds which can exhibit biological activity. As potential drugs they could be employed in antisense strategy by acting on the pathogenic mRNA, causing inactivation of the target molecules during the translation process [1]. Ideal antisense agent (ASO) should be resistant to exo and/or endonucleases, exhibit a suitable pharmacological and pharmacokinetic profile and exhibits high binding affinity towards the target mRNA. To improve some properties of the ASO plethora of the chemical modifications introduced within the nucleobase, sugar unit and internucleotide linkage are investigated [3]. Among them, phosphorothioate oligonucleotides (PS-oligo), created by replacing one of the nonbridging oxygen atoms with a sulfur atom, are the major representatives of DNA analogs. PS-oligo display several attractive features like nuclease resistance, activation of RNase H, and good pharmacokinetic properties [1]. Replacement of one of two nonbridging oxygens at phosphorus by sulfur induces asymmetry at the phosphorus atom. Hence, the synthesized oligo(nucleoside phosphorothioate) is a mixture of 2n diastereomers (where n is the number of internucleotide phosphorothioate functions). Therefore the actual biological activity of the P-chiral oligonucleotide analogues, (e.g., interactions with proteins or nucleic acids) may depend on stereochemical factors [7]. One has to keep in mind that the phosphoramidite [5] and H-phosphonate [32] methodologies (commonly used to prepare PS-oligo) are nonstereospecific and give a mixture of 2n diastereomers. Thus, various methods have been elaborated to synthesize these P-chiral oligonucleotide analogs in a stereocontrolled manner [15, 17], among them the oxathiaphospholane method developed by Stec et al. [18], the method utilizing nucleoside 3’-O-(3-N-acyl)oxazaphospholidine derivatives as monomer units [19], and the method based on a stereoselective synthesis of nucleoside 3’-O-oxazaphospholidine monomers [21, 22] are the most significant.
    Źródło:
    Wiadomości Chemiczne; 2015, 69, 11-12; 957-981
    0043-5104
    2300-0295
    Pojawia się w:
    Wiadomości Chemiczne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Molekularne podłoże i terapia rdzeniowego zaniku mięśni
    Molecular basis and therapy of spinal muscular atrophy
    Autorzy:
    Szczerba, Anna
    Śliwa, Aleksandra
    Żarowski, Marcin
    Jankowska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/2045802.pdf
    Data publikacji:
    2018
    Wydawca:
    Polskie Towarzystwo Neurologów Dziecięcych
    Tematy:
    rdzeniowy zanik mięśni
    gen SMN
    białko SMN
    antysensowe oligonukleotydy
    nusinersen
    terapia genowa
    AVXS
    spinal muscular atrophy
    SMN gene
    SMN protein
    antisense oligonucleotides Spinraza
    gene therapy
    Zolgensma
    Opis:
    Rdzeniowy zanik mięśni, SMA (spinal muscular atrophy) to genetyczna choroba powodowana mutacją genu SMN1 i w konsekwencji niedoborem białka SMN (survival of motor neuron), które odgrywa kluczową rolę w regulacji ekspresji genów w motoneuronach. Jego brak prowadzi do zwyrodnienia i apoptozy komórek rogów przednich rdzenia kręgowego i w konsekwencji zaniku mięśni. Gen SMN w ludzkim genomie występuje w co najmniej dwóch kopiach: SMN1 i SMN2. Oba geny kodują identyczne białko, jednak transkrypty SMN1 mają pełną długość (FL-SMN), a 90% transkryptów SMN2 jest pozbawiona eksonu 7 (SMN-Δ7), co powoduje niefunkcjonalność białka. FL-SMN jest niezbędne do prawidłowego przeprowadzenia procesu splicingu. Niskie stężenie białka SMN upośledza także dynamikę szkieletu aktynowego, co skutkuje zahamowaniem wzrostu aksonów motoneuronów. Dotychczasowe leczenie SMA opierało się głównie na działaniach neuroprotekcyjnych i wzmacniających siłę mięśni. Obecnie, dzięki wykorzystaniu antysensowych nukleotydów (ASO), możliwa jest terapia modulująca przebieg splicingu, która pozwala na włączenie eksonu 7 do transkryptu SMN2. Takim ASO jest nusinersen, który został zatwierdzony do użytku w USA i Europie; jest on w pełni refundowany w Polsce. Terapeutyk jest przeznaczony do leczenia pacjentów ze wszystkimi typami SMA w każdym wieku. Inną strategią leczenia jest terapia genowa pod nazwą onasemnogene abeparvovec (AVXS-101), polegająca na wprowadzeniu do organizmu pacjenta prawidłowej kopii genu SMN1. Nośnikiem genu terapeutycznego, wnikającego jedynie do komórek układu nerwowego, jest wektor wirusowy AAV. Lek ten został zatwierdzony przez FDA w leczeniu SMA pacjentów poniżej 2. roku życia.
    Spinal muscular atrophy (SMA) is a genetic disorder caused by mutations in the SMN1 gene and, consequently, a deficiency of the SMN (survival of motor neuron) protein, which plays a key role in regulating gene expression in motoneurons. Its absence leads to degeneration and apoptosis of the anterior horn cells of the spinal cord and, as a consequence, to muscular atrophy. In the human genome the SMN gene is found in at least two copies: SMN1 and SMN2. Both genes encode the same protein, however, SMN1 transcripts are full-length (FL-SMN) and 90% of SMN2 transcripts are deprived of exon 7 (SMN-Δ7), which causes the protein to be non-functional. FL-SMN is necessary for proper splicing process. Low concentration of the SMN protein also impairs the dynamics of the actin skeleton, which results in inhibition of motoneuron axon growth. Hitherto SMA treatment was based mainly on neuroprotective and muscle strength enhancing approaches. Currently, thanks to the use of antisense nucleotides (ASO), it is possible to modulate the splicing process of SMN2, which allows the incorporation of exon 7 into the SMN2 transcripts. Nusinersen is an ASO that has been approved for clinical use in USA and Europe; it is fully refunded in Poland. The therapy is intended for the treatment of patients with all types of SMA at all ages. Another treatment strategy is the gene therapy called onasemnogene abeparvovec (AVXS-101) which allows introducing the correct copy of the SMN1 gene into the patient’s body. The carrier of the therapeutic gene that enters only the cells of the nervous system is an AAV viral vector. This drug has been approved by the FDA for the treatment of SMA in patients under 2 years of age.
    Źródło:
    Neurologia Dziecięca; 2018, 27, 55; 39-46
    1230-3690
    2451-1897
    Pojawia się w:
    Neurologia Dziecięca
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Zastosowanie cieczy jonowych jako modyfikatorów fazy ruchomej w chromatografii cieczowej
    Application of ionic liquids as mobile phase modifiers in liquid chromatorgaphy
    Autorzy:
    Kilanowska, Anna
    Zielak, Judyta
    Studzińska, Sylwia
    Powiązania:
    https://bibliotekanauki.pl/articles/172012.pdf
    Data publikacji:
    2020
    Wydawca:
    Polskie Towarzystwo Chemiczne
    Tematy:
    ciecze jonowe
    chromatografia cieczowa
    blokowanie wolnych silanoli
    chromatografia par jonowych
    oligonukleotydy antysensowne
    ionic liquids
    liquid chromatography
    free silanol suppressors
    ion pair chromatography
    antisense oligonucleotides
    Opis:
    Ionic liquids are molten salts composed of large, asymmetric, organic cations (e.g. imidazolium or piperidine) and inorganic anions such as e.g chloride or fluoroborate. These compounds are characterized by low melting point, below 1000C, however, they also have other interesting properties including high thermal stability, minor vapor pressure or negligible volatility. Moreover, by the appropriate selection of the cation and anion building the ionic liquid, it is possible to obtain the desired physicochemical properties of these salts. For this reason, ionic liquids are applied to the synthesis, catalysis, electrochemical methods, extraction methods, etc. Application of these compounds in separation techniques merits special attention, especially considering liquid chromatography. Ionic liquids are commonly used in this technique as free silanols suppressors, especially regarding the analysis of basic compounds. Moreover, the excess amount of ionic liquids ions may adsorb on the hydrophobic ligands present at the stationary phase surface, which also plays a significant role in the retention of analytes. Besides their application as silanols suppressors, these compounds were also used as ion pair reagents in the analysis of antisense oligonucleotides, which are short nucleic acid fragments with therapeutic potential due to the ability to bind with complementary sequences of ribonucleic acid. For this reason, antisense oligonucleotides are used in the treatment of several diseases. This article briefly presents structures, properties and the application of ionic liquids as mobile phase modifiers for the analysis of the wide range of different analytes using liquid chromatography. Moreover, a part of this paper was devoted to the analysis of antisense oligonucleotides with the use of the different chromatographic techniques, including the application of ionic liquids as mobile phase additives in ion pair chromatography.
    Źródło:
    Wiadomości Chemiczne; 2020, 74, 7-8; 507-525
    0043-5104
    2300-0295
    Pojawia się w:
    Wiadomości Chemiczne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Antisense hairpin loop oligonucleotides as inhibitors of expression of multidrug resistance-associated protein 1: Their stability in fetal calf serum and human plasma.
    Autorzy:
    Rębowski, Grzegorz
    Wójcik, Marzena
    Boczkowska, Małgorzata
    Gendaszewska, Edyta
    Soszyński, Mirosław
    Bartosz, Grzegorz
    Niewiarowski, Wojciech
    Powiązania:
    https://bibliotekanauki.pl/articles/1044049.pdf
    Data publikacji:
    2001
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    human plasma
    3' -exonuclease activity
    multidrug resistance-associated protein
    fetal calf serum
    antisense hairpin loop oligonucleotides
    Opis:
    Multidrug resistance-associated protein (MRP1) is a transmembrane pump protein responsible for the efflux of chemotherapeutic drugs, an important cause of anticancer treatment failure. Trying to circumvent MRP-mediated resistance we designed and synthesized hairpin loops forming antisense oligodeoxyribonucleotides (ODNs), both phosphodiesters (PO-ODNs) and their phosphorothioate analogues (PS-ODNs), to reduce the protein expression by targeting its mRNA in a sequence specific manner. Melting temperature measurements as well as polyacrylamide gel electrophoresis supported the preferential formation of a secondary structure, which was expected to protect ODNs against 3'-exonuclease degradation. ODNs and PS-ODNs designed in this work were successfully tested as antisense inhibitors of the expression of MRP1 in the leukaemia HL60/ADR cell line. Foreseeing the necessity to perform clinical studies with such ODNs we investigated their stability against the 3'-exonuclease activity of fetal calf serum and human plasma. Under the conditions, corresponding to physiological ones, we observed high stability of hairpin loop forming ODNs, especially those containing longer (e.g. 7 base pair) stems. Comparative studies on the stability of chemically unmodified hairpin loop forming ODNs and their PS-counterparts indicated that endonuclease activity did not play any important role in the process of their nucleolytic degradation. Our studies provide strong evidence for high stability of chemically unmodified hairpin loop ODNs, making them an attractive alternative to phosphorothioate analogues commonly used in antisense strategy.
    Źródło:
    Acta Biochimica Polonica; 2001, 48, 4; 1061-1076
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-11 z 11

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies